Insight Wealth Strategies’s Bio-Rad Laboratories Class A BIO Stock Holding History

Insight Wealth Strategies’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$246K	Sell	827 -12	-1%	-$3.4K	0.02%	170
2026 Q1	$234K	Hold	839	–	–	0.03%	168
2025 Q4	$254K	Sell	839 -67	-7%	-$20.9K	0.03%	160
2025 Q3	$254K	Hold	906	–	–	0.03%	160
2025 Q2	$225K	Hold	906	–	–	0.03%	160
2025 Q1	$221K	Hold	906	–	–	0.03%	149
2024 Q4	$298K	Hold	906	–	–	0.04%	137
2024 Q3	$303K	Hold	906	–	–	0.04%	142
2024 Q2	$247K	Hold	906	–	–	0.04%	149
2024 Q1	$313K	Buy	+906	New	+$298K	0.05%	145

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Insight Wealth Strategies's BIO Position: Q2 2026 in Review

Insight Wealth Strategies reduced its Bio-Rad Laboratories Class A (BIO) stake by 1.4% in Q2 2026, selling an estimated $3.4K and leaving 827 shares worth $246K. The position accounts for 0.02% of the portfolio, ranked #170.

Insight Wealth Strategies first reported a position in BIO in Q1 2024 and has held it in 10 quarters since. The position peaked at $313K in Q1 2024. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Insight Wealth Strategies held 827 shares of Bio-Rad Laboratories Class A worth $246K as of Q2 2026.
Insight Wealth Strategies sold 12 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $3.4K.
Bio-Rad Laboratories Class A made up 0.02% of Insight Wealth Strategies's portfolio in Q2 2026, its #170 holding.
Insight Wealth Strategies first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and has held it in 10 quarters since.
Insight Wealth Strategies's Bio-Rad Laboratories Class A position peaked at $313K in Q1 2024.
398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Insight Wealth Strategies's 13F filing for Q2 2026, filed 10 Jul 2026.